Scientists Target Ceramides to Prevent Acute Kidney Injury: What the New Research Means

A new preclinical study has identified a potential metabolic strategy to prevent acute kidney injury (AKI), a sudden and potentially life-threatening decline in kidney function. Researchers at University of Utah Health found that fatty molecules called ceramides contribute to kidney injury by damaging mitochondria, the energy-producing structures inside kidney cells. In mouse models, altering ceramide metabolism protected mitochondrial function and prevented kidney injury.

The findings, published in Cell Metabolism, are promising because there are currently no approved medicines specifically for treating AKI. However, the research remains preclinical: it has not yet established whether the same approach is safe or effective in humans.

What is acute kidney injury?

Acute kidney injury is a rapid loss of kidney function that can occur after major physiological stress, including sepsis, major surgery, or cardiac procedures. It is common among critically ill patients and can increase the risk of developing long-term chronic kidney disease.

Unlike chronic kidney disease, which often develops gradually, AKI can emerge quickly after an acute insult. Early identification and prevention are therefore especially important for high-risk patients, including those undergoing heart surgery.

Ceramides and mitochondrial damage

Ceramides are a class of lipid molecules involved in cellular signalling and metabolism. The University of Utah team found that ceramide levels rose sharply after kidney injury in mouse models and in human urine samples. Higher ceramide levels were associated with more severe kidney injury.

The researchers found that ceramides damaged mitochondria in kidney cells. Mitochondria supply the energy required for normal cellular function; when they become distorted or inefficient, kidney cells are less able to withstand injury.

What the researchers did

The study tested two related approaches to reducing harmful ceramide activity:

• Genetic modification: The researchers altered the genetic programme controlling ceramide production in mice. These modified mice did not develop AKI under conditions that normally caused severe kidney damage.
• Drug candidate testing: The team also tested a ceramide-lowering drug candidate developed by Centaurus Therapeutics. Mice treated before injury maintained normal kidney function, remained active, and showed kidney structure that appeared close to normal under microscopic examination.

The study’s central observation was that reducing ceramide activity preserved mitochondrial structure and function, even under conditions that would normally damage kidney cells.

Could ceramides become an early warning marker?

One of the most clinically interesting findings is that ceramide levels increased rapidly after kidney injury and correlated with injury severity. This suggests that urinary ceramides could eventually serve as an early biomarker for AKI.

If validated in larger human studies, such a biomarker could help clinicians identify patients at high risk before symptoms appear. For example, it could support closer monitoring of patients preparing for procedures known to carry a high risk of AKI, such as cardiac surgery.

Why the findings matter

AKI is a major clinical challenge because it can progress rapidly and may leave patients vulnerable to permanent kidney damage. A therapy that protects mitochondrial health could represent a meaningful shift from managing consequences of injury toward preventing cellular damage before it becomes severe.

The researchers also suggest that the approach may have relevance beyond kidney disease. Mitochondrial dysfunction is associated with several conditions, including heart failure, diabetes, and fatty liver disease, although those possibilities remain speculative at this stage.

Important limitations

• Despite the encouraging results, this is not yet a treatment for kidney disease in people.
• The study was conducted in mice, and animal results do not always translate to humans.
• The drug candidate used in the study is related to, but not identical to, a ceramide-lowering drug that has entered human clinical testing.
• The intervention was given before injury in the mouse model. It is not yet clear whether the same approach would work when treatment begins after kidney injury has already occurred.
• Safety, long-term effects, dosing, drug metabolism, and side effects would need careful evaluation in human trials.
• The researchers themselves emphasise that the work remains preclinical and that further due diligence is required before moving the approach into patients.

What this means for patients

For now, people should not interpret this research as evidence that kidney damage can simply be reversed through a new supplement, diet, or over-the-counter treatment. The study describes an experimental metabolic intervention tested in animal models, not an approved therapy.

Patients with kidney disease, diabetes, high blood pressure, or a history of kidney injury should continue to follow individualised medical advice. Regular monitoring of kidney function, blood pressure, blood sugar, medication use, and hydration status remains central to protecting kidney health.

Research direction

This study adds to a broader research effort to understand how kidney injury begins at the cellular level and how it might be prevented before irreversible damage develops. By focusing on ceramide metabolism and mitochondrial health, the University of Utah team has identified a promising biological pathway for future AKI therapies.

The next step will be rigorous human research to determine whether ceramide-targeted interventions can safely reduce AKI risk in vulnerable patient groups. If successful, the work could eventually support earlier risk detection, preventive treatment before high-risk procedures, and new approaches to protecting kidney function during critical illness.

Source

Nicholson, R. J., Cedeño-Rosario, L., Maschek, J. A., et al. “Therapeutic remodeling of the ceramide backbone prevents kidney injury.” Cell Metabolism, 2025. DOI: 10.1016/j.cmet.2025.10.006.